ZURICH (Reuters) - Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses.


110


Reuters

Latest News

CBC: On ice collision being called Tonya Harding 2.0

WashingtonPost: Kaila Charles has moved past the foul calls and led Maryland women’s basketball forward

NewYorkTimes: Mueller Delivers Report on Russia Investigation to Attorney General

FOX: Fox News Brief 03-22-2019 05PM

CBC: Indonesian airline wants to cancel Boeing order after crash

CBC: WestJet sticking with Boeing 737 Max once planes certified to fly

BBC: Russia-Trump inquiry: Special Counsel Robert Mueller ends Russia investigation

WashingtonPost: For Bayer and FedEx, Deal Hindsight is 20/20

FOX: Mueller submits long-awaited Russia probe report to Justice Department

CNN: Quickly catch up on the day's news

CBS: Mueller submits long-awaited report to attorney general

CBC: Coast guard helping adrift tanker carrying 8M litres of fuel near southwest Newfoundland

CBC: Robert Mueller's report delivered to U.S. attorney general

BBC: Brexit: Vote on Theresa May's deal may not happen next week

FOX: Mueller submits long-awaited Russia probe report to Justice Department

FOX: Scientists may have found way to ‘reverse’ alcoholism in rats

FOX: Mueller submits long-awaited Russia probe report to Justice Department

CNN: Pompeo agrees it's possible God raised Trump to protect Israel

CBS: Mueller submits Russia report

BBC: Yorkshire tourism boss quits after expenses probe

ABC: Who is special counsel and former FBI director Robert Mueller?

ABC: Special counsel Robert Mueller's report handed off to Department of Justice

FOX: Scientists may have found way to ‘reverse’ alcoholism in rats

13 Related Articles, between 2018-02-16 and 2018-02-15